Mesoblast has acquired a world-wide licence to use a patented technology incorporating the use of certain adult stem cells for orthopaedic applications. The licence covers all divisional filings, continuation-in-parts applications, and new applications representing improvements to the technology.

The intellectual property was fully assigned to Angioblast Systems by the Institute of Medical and Veterinary Science (IMVS) and the Hanson Institute in Adelaide, South Australia, where the MPC technology was discovered.

The adult stem cells, called Mesenchymal Precursor Cells (MPC), can be obtained from various sites in the body, grown in large numbers and differentiated into specialised tissues such as bone, cartilage, blood vessels and heart muscle, for use in conditions requiring tissue regeneration and repair.

The patented technology enables:

• precise identification and isolation of MPCs, resulting in a much purer and more potent starting population of adult stem cells

• more efficient expansion and scale-up of the isolated adult stem cell population, giving rise to more potent and effective products and lower costs of production

• generation of universal products for use in any recipient due to lack of immune rejection, enabling implementation of the sustainable business models typical of high-margin pharmaceutical products

• product development targeting a wide range of commercial applications and markets for diseases with unmet clinical needs;

• development of cell-based products without the ethical issues surrounding the use of embryonic stem cells

The Technology


 

Last Share Price

August 26 2010- Preliminary 2010 Annual Report

August 26 2010 - Mesoblast Financial Year End Results; Strong Clinical Progress, Major Regulatory Milestone and Enhanced Corporate Strategy

23 August 2010 - EGM documents - Letter from the Chairman, Notice of Meeting, Independent Expert Report.

16 August - Mesoblast on track for phase 3 bone marrow transplant trial following positive meeting with FDA

21 July - Mesoblast receives TGA regulatory approval to commercially manufacture adult stem cell products

12 July - Phase 3 meeting scheduled with FDA following positive results of bone marrow regeneration trial

28 May - Mesoblast featured at ASX Singapore conference highlighting emerging market leaders

19 May - United States FDA Clears Phase 2 Trial for Cervical Spinal Fusion

16 August 2010 - Southern Cross Equities research - Phase III getting ready for takeoff

23 July 2010 - Southern Cross Equities Research – Big Pharma will be watching

21 July 2010 - Southern Cross Equities Research – The clinical endgame nears

17 May 2010 - Southern Cross Equities Research – Capitalising the Stem Cell Opportunity

14 May 2010 - Bioshares

26 February - RBS Equities Research - Mesoblast (Buy) 1H10 - Master Blasters

July 2009 - Chairman’s Letter

May 2009 - Chairman’s Letter

May 2008 - Issue Nine